Liraglutide

Compound Overview

Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native GLP-1. The compound includes a C-16 palmitic acid modification that supports non-covalent albumin binding, giving it an extended research half-life relative to native GLP-1 while remaining shorter than Semaglutide. In controlled laboratory systems, it activates GLP-1 receptors involved in glucose homeostasis and metabolic signaling.

Research Background & Published Literature

Liraglutide is widely referenced in GLP-1 receptor pharmacology literature, including published LEAD and SCALE research programs. Researchers use it as a benchmark compound for studying GLP-1 receptor activity and metabolic signaling pathways in controlled experimental contexts.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Marso et al. (2016) — N Engl J Med

Storage, Handling & Stability Guidelines

For long-term stability, store lyophilized Liraglutide at -20°C. After reconstitution with sterile diluent, keep the preparation refrigerated at 2–8°C and reduce freeze-thaw exposure by aliquoting working volumes according to your laboratory's standard operating procedures.

• Keep ambient-temperature handling time as short as practical to support compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.